Clinical Trial

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

Name: Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy — clinical trial record (NCT07499882)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.

Trial Details

NCT Number	NCT07499882
Lead Sponsor	Christian Hospital Northeast Northwest Collaborators: TerSera Therapeutics LLC, TeamHealth
Conditions	Chemotherapy Induced Peripheral Neuropathy (CIPN)
Enrollment	24 participants
Start Date	2026-05-02
Primary Completion	2028-05-01 (estimated)
Study Completion	2028-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-30